Other languages GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
3.12 ^USD	-4.59%		-6.17%	-59.22%

03-26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Caterpillar deja París, el cacao está menos caliente	04-30
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud	04-30
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	02-01
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	12-04
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	11-06
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
GT Biopharma, Inc. Announces Board Changes	04/05/23
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
GT Biopharma to Sell 6.5 Million Shares and Warrants, Expects Gross Proceeds of $6.5 Million	30/12/22
Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer	14/12/22
GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee	13/12/22
GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia	12/12/22
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	31/10/22
GT Biopharma Files $150 Million Mixed Shelf	14/10/22
GT Biopharma Taps Cytovance Biologics as Manufacturing Partner for Leukemia Drug	31/08/22
Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650	30/08/22
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Other languages

Filters